Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034199046> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2034199046 endingPage "A617" @default.
- W2034199046 startingPage "A617" @default.
- W2034199046 abstract "Trogftazone reduces fibrosis formation and progression in an experimental model of chronic pancreatitis in mice. Background: Peroxisome proliferator activated receptor gamma (PFARgamma) conu~:~ls growth, dilferentistion, and inflammation. Aim: To determine the influence of troglitazone, a figand for PPAR-gamma, on fibrosis and pancreatic damage in a mouse model of chronic pancreatitis. Methods: Mice received six hourly intraperitoneal injections ~4th 50 mg/kg cerulein (to induce pancreatins) or NACL (control), three times a week for six weeks. Seven weeks after the first injection all mice were sacrificed, Five groups were compared, i.e. A: NACL injections, B: NACL injections, chow' mixed with 0.2% troglitazone, C: cerulein iujections, D: cerulein injections, chow mLxed with troglitasone, E: cerulein injections, chow mixed with troglitazone during last 3 weeks only,. End points were pancreas weight, pancreas histology (abnormal architecture, glandular atrophy, pseudotubular complexes), collagen formation (sirius red staining to quantify fibrosis; image analysis), pancreas amylase and hydroxyproline content, TGF beta (in pancreas and plasma), and plasma soluble TNF receptor levels. The number of activated stellate cells was detected by immunohistochemistry. Results: Group C had developed chronic panereatitis after 7 weeks (all parameters P < 0.05, C vs At. Troglitazone given either for seven weeks or only for the last three weeks, reduced pancreatic damage (histology, amylase and hydroxyproline content), collagen formation, TGF beta and sTNF receptor levels and the number of activated stellate cells (P<O.05, D or E vs C; nonsignificant for D vs E). Conclusion: Troglitazone blocks activation of pancreatic stellate cells and reduces fibrosis formation and pancreatic damage in experimental chronic pancreatitis Troglitazone remains beneficial in a therapeutic setting when given after initial da:nage has been established." @default.
- W2034199046 created "2016-06-24" @default.
- W2034199046 creator A5011952821 @default.
- W2034199046 creator A5036345568 @default.
- W2034199046 creator A5042869763 @default.
- W2034199046 creator A5048965254 @default.
- W2034199046 creator A5069227141 @default.
- W2034199046 date "2003-04-01" @default.
- W2034199046 modified "2023-09-25" @default.
- W2034199046 title "Troglitazone reduces fibrosis formation and progression in an experimental model of chronic pancreatitis in mice" @default.
- W2034199046 doi "https://doi.org/10.1016/s0016-5085(03)83124-4" @default.
- W2034199046 hasPublicationYear "2003" @default.
- W2034199046 type Work @default.
- W2034199046 sameAs 2034199046 @default.
- W2034199046 citedByCount "0" @default.
- W2034199046 crossrefType "journal-article" @default.
- W2034199046 hasAuthorship W2034199046A5011952821 @default.
- W2034199046 hasAuthorship W2034199046A5036345568 @default.
- W2034199046 hasAuthorship W2034199046A5042869763 @default.
- W2034199046 hasAuthorship W2034199046A5048965254 @default.
- W2034199046 hasAuthorship W2034199046A5069227141 @default.
- W2034199046 hasBestOaLocation W20341990461 @default.
- W2034199046 hasConcept C126322002 @default.
- W2034199046 hasConcept C170493617 @default.
- W2034199046 hasConcept C187345961 @default.
- W2034199046 hasConcept C2775967933 @default.
- W2034199046 hasConcept C2778150266 @default.
- W2034199046 hasConcept C2780559512 @default.
- W2034199046 hasConcept C502942594 @default.
- W2034199046 hasConcept C71924100 @default.
- W2034199046 hasConceptScore W2034199046C126322002 @default.
- W2034199046 hasConceptScore W2034199046C170493617 @default.
- W2034199046 hasConceptScore W2034199046C187345961 @default.
- W2034199046 hasConceptScore W2034199046C2775967933 @default.
- W2034199046 hasConceptScore W2034199046C2778150266 @default.
- W2034199046 hasConceptScore W2034199046C2780559512 @default.
- W2034199046 hasConceptScore W2034199046C502942594 @default.
- W2034199046 hasConceptScore W2034199046C71924100 @default.
- W2034199046 hasIssue "4" @default.
- W2034199046 hasLocation W20341990461 @default.
- W2034199046 hasOpenAccess W2034199046 @default.
- W2034199046 hasPrimaryLocation W20341990461 @default.
- W2034199046 hasRelatedWork W1769195190 @default.
- W2034199046 hasRelatedWork W1849605568 @default.
- W2034199046 hasRelatedWork W1970094770 @default.
- W2034199046 hasRelatedWork W2023981456 @default.
- W2034199046 hasRelatedWork W2049659899 @default.
- W2034199046 hasRelatedWork W2058553057 @default.
- W2034199046 hasRelatedWork W2096119759 @default.
- W2034199046 hasRelatedWork W2110075919 @default.
- W2034199046 hasRelatedWork W2121508402 @default.
- W2034199046 hasRelatedWork W2418161723 @default.
- W2034199046 hasVolume "124" @default.
- W2034199046 isParatext "false" @default.
- W2034199046 isRetracted "false" @default.
- W2034199046 magId "2034199046" @default.
- W2034199046 workType "article" @default.